(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 August 2020 (20.08.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/167593 A1

(51) International Patent Classification:
C12N 15/113 (2010.01) *A61K 31/713* (2006.01)
C12N 15/11 (2006.01)

(21) International Application Number:
PCT/US2020/017129

(22) International Filing Date:
07 February 2020 (07.02.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/804,410 12 February 2019 (12.02.2019) US

(71) Applicant: **DICERNA PHARMACEUTICALS, INC.** [US/US]; 33 Hayden Avenue, Lexington, Massachusetts 02421 (US).

(72) Inventor: **SAXENA, Utsav**; 33 Hayden Avenue, Lexington, Massachusetts 02421 (US).

(74) Agent: **REID, Andrea L.C.** et al.; One International Place, 40th Floor, 100 Oliver Street, Boston, Massachusetts 02110-2605 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: METHODS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF CYP27A1

(57) Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing CYP27A1 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of CYP27A1 expression may be double-stranded or single-stranded and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of CYP27A1 expression may also include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat hepatobiliary disease and related conditions (e.g., liver fibrosis).

WO 2020/167593 A1